Codexis, Inc. (CDXS) has a MoatMap StockRank of 36/100 based on Quality (27/100), Value (39/100), and Momentum (57/100) factor scores. The current signal is HOLD. Codexis develops engineered enzymes that optimize pharmaceutical manufacturing processes. This biocatalysis platform is highly relevant to the CDMO pricing power cycle as a second-order efficiency enabler, but the company is still transitioning to consistent profitability and faces customer concentration risks.
Codexis, Inc. is a leading company in enzyme engineering and biocatalysis, providing sustainable solutions for the pharmaceutical, food and beverage, and industrial sectors. The company possesses a proprietary CodeEvolver® enzyme engineering platform, allowing for rapid development of highly specific and efficient enzymes. It is a specialized biotechnology company at the forefront of enzyme engineering, providing critical biocatalytic solutions for greener and more efficient manufacturing.
| Price | $2.47 |
| Market Cap | $250M |
| P/E (Forward) | -7.57 |
| Price/Book | 5.88 |
| Return on Equity | -68.9% |
| Return on Invested Capital | -31.9% |
| Debt/Equity | 168.62 |
| Gross Margin | 23.8% |
| Operating Margin | -52.7% |
| Revenue Growth | 102.1% |
| Free Cash Flow | $-8M |
Codexis, Inc. operates in the Biotechnology industry, part of the Healthcare sector (United States).